Abstract
Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.
| Original language | English |
|---|---|
| Pages (from-to) | e306-e318 |
| Journal | Clinical Breast Cancer |
| Volume | 19 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2019 |
Fingerprint
Keywords
- Adverse events
- Metastatic breast cancer
- Objective response rate
- Overall survival
- Progression-free survival
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : A Retrospective Comparison of Efficacy and Safety Profiles. / Vernieri, Claudio; Prisciandaro, Michele; Milano, Monica; Cona, Maria Silvia; Maggi, Claudia; Brambilla, Marta; Mennitto, Alessia; Fabbroni, Chiara; Farè, Elena; Cresta, Sara; Celio, Luigi; Mariani, Gabriella; Bianchi, Giulia; Capri, Giuseppe; de Braud, Filippo.
In: Clinical Breast Cancer, Vol. 19, No. 2, 04.2019, p. e306-e318.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer
T2 - A Retrospective Comparison of Efficacy and Safety Profiles
AU - Vernieri, Claudio
AU - Prisciandaro, Michele
AU - Milano, Monica
AU - Cona, Maria Silvia
AU - Maggi, Claudia
AU - Brambilla, Marta
AU - Mennitto, Alessia
AU - Fabbroni, Chiara
AU - Farè, Elena
AU - Cresta, Sara
AU - Celio, Luigi
AU - Mariani, Gabriella
AU - Bianchi, Giulia
AU - Capri, Giuseppe
AU - de Braud, Filippo
PY - 2019/4
Y1 - 2019/4
N2 - Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.
AB - Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.
KW - Adverse events
KW - Metastatic breast cancer
KW - Objective response rate
KW - Overall survival
KW - Progression-free survival
UR - http://www.scopus.com/inward/record.url?scp=85059582368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059582368&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2018.12.004
DO - 10.1016/j.clbc.2018.12.004
M3 - Article
C2 - 30635175
AN - SCOPUS:85059582368
VL - 19
SP - e306-e318
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 2
ER -